Date: 2015-11-10
Type of information: Nomination
Compound: chairman of the board of directors
Company: Asceneuron (Switzerland)
Therapeutic area: Neurodegenerative diseases
Type agreement: nomination
Action mechanism:
Disease:
Details:
- • On November 10, 2015, Asceneuron announced the appointment of Hans Schikan (PharmD) as non-executive chairman to the board of directors. Hans Schikan is former chief executive officer of Prosensa, a biopharmaceutical company focusing on novel RNA modulating treatments for rare diseases like Duchenne muscular dystrophy. The company was acquired by BioMarin early 2015 for up to $ 840 million.
- Before joining Prosensa, Hans worked at Genzyme, including as vice president for global marketing and strategic development of Genzyme’s product portfolio for rare genetic diseases. Prior to Genzyme, he worked at Organon, both at corporate level and in country operations which included assignments in Asia and Europe. Hans is currently chairman of the board of Complix (Belgium) and InteRNA Technologies (Netherlands). In addition, he is board member of Hansa Medical, Sobi and Wilson Therapeutics (Sweden). He is also member of the top team of the Dutch Top Sector Life Sciences & Health and Adviser of Khondrion (Netherlands).
Financial terms:
Latest news:
Is general: Yes
